Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.
about
hERG1 Potassium Channels: Novel Biomarkers in Human Solid CancersWT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma.The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer CellsA meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction.Sonic hedgehog-Gli1 signaling pathway regulates the epithelial mesenchymal transition (EMT) by mediating a new target gene, S100A4, in pancreatic cancer cellsRole of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma.Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma.Tumor size as measured at initial X-ray examination, not length of bile duct stricture, predicts survival in patients with unresectable pancreatic cancer.CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer.Expression of c-fos was associated with clinicopathologic characteristics and prognosis in pancreatic cancerhERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival.Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancerHLA-G impairs host immune response and predicts poor prognosis in pancreatic cancerNuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer.Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM)High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.Immunohistochemistry of pancreatic neoplasiaA meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.A proposed model for prediction of survival based on a follow-up study in unresectable pancreatic cancer.Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinomaPrognostic Evaluation of Vimentin Expression in Correlation with Ki67 and CD44 in Surgically Resected Pancreatic Ductal Adenocarcinoma.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinomaIncreased FAT10 expression is related to poor prognosis in pancreatic ductal adenocarcinoma.MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer.Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.Long-term survivors after pancreatectomy for cancer: the TNM classification is outdated.Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.Pancreatic cancer: translational research aspects and clinical implications.Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma.High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma.Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma.The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend?Prognostic significance of tumor mitotic rate in T2 melanoma staged with sentinel lymphadenectomy.
P2860
Q26784422-7D909121-8180-4387-9FF8-9B9AA6908374Q33598160-243DD126-21B0-4031-B382-4CD25CC7ABFDQ33826323-43D13C13-2895-41BB-A189-DD7A4539D4FDQ33953987-35D85122-2345-4E2D-833F-CCCC18AE56E0Q33967252-2320038D-AAB9-4009-AA22-9F404BC7EED7Q33982773-7CC5354D-900C-4D89-8310-C9A2A0EDE29FQ34385867-16CC3126-574B-4DA9-AA15-7461CBFFFDF8Q34389137-407BF7C5-A831-42AE-A83D-99F6D1DA0D56Q34421240-A3BDA444-FA6F-4731-B555-6EEC7B77AB95Q34537885-BB94106F-9FE2-42BA-BCE3-541AFA7F6E6FQ35196594-24D6147B-1155-46B9-973A-1BEAAF26A054Q35198312-ABAEDFB6-0424-4673-B648-53700BA37195Q35320095-4CB9B0FB-0E03-40E9-9BD3-3719486F9687Q35656610-C305C300-9F2F-4596-9E9F-A2425D6FD954Q35820525-D1A1DD82-3D0D-4179-88C5-2F932DA4CBCDQ36166827-730619C4-2472-41B3-B4A1-14B6F43E893FQ36309539-BEC08E3A-5E02-4B43-B773-4FF9893B0F03Q36464545-1098E8C4-EAEB-4F7E-BE3F-A9B316F9C66EQ36525188-ABED982B-C397-406B-B055-BAA59D9C9B6BQ36578336-B9521F9F-B6F2-4F9D-AF23-1A0F91B63C8AQ36796262-90AD14D9-F604-4A8B-88F1-D38153BECA80Q36921334-30CA7B5B-7699-4F45-ADB0-69FC4C64944DQ37268613-16DDD1A0-EDF5-424D-8C14-495DA2E24995Q37448561-3A0059AF-759F-41F4-BC83-F42327A801E3Q37717226-8DC46D19-4E38-4CD9-8D40-04C63DA966F4Q37738137-FAB5BB1D-0961-491B-B3FA-97B154CEE2EAQ38125770-162B2722-1CC9-4DC7-93C7-E9820E94E9D9Q38378638-A9815A3C-CF82-4F66-9924-32AAEE20C6DDQ38393047-C697EE3D-A910-45DF-B0E8-3FF1BB0102ADQ39146473-066B61AE-3DCB-459D-B134-F154BD5C2978Q39169243-3D13F18D-15F4-4CB6-9A08-C22F0D5679CBQ41431657-478BC880-1F0C-45CB-A7A1-C19FAE3AE9DAQ42273391-7C937775-9349-4D19-8684-C03E424BED59Q42556570-5A5C4A3D-2408-416B-BCDC-862E9C91CC50Q44592465-4EC78FBA-B91A-446A-A307-DCC0DFD37606Q45205085-877CFE21-AD4A-4E11-A506-DFCC436E7989Q47163638-17FC3958-103A-4E0E-8A94-0EFE6531EDCAQ47336139-0B2F677D-3770-4AFE-8CFA-9A9D83CF08FBQ51399534-C853BA1B-C8CE-47AE-8ADE-68232E6AAC76Q52968768-536E7C0C-B2A8-406D-B74D-859B78C77C6E
P2860
Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systematic review of immunohis ...... tients with pancreatic cancer.
@en
Systematic review of immunohis ...... tients with pancreatic cancer.
@nl
type
label
Systematic review of immunohis ...... tients with pancreatic cancer.
@en
Systematic review of immunohis ...... tients with pancreatic cancer.
@nl
prefLabel
Systematic review of immunohis ...... tients with pancreatic cancer.
@en
Systematic review of immunohis ...... tients with pancreatic cancer.
@nl
P2093
P2860
P921
P356
P1476
Systematic review of immunohis ...... tients with pancreatic cancer.
@en
P2093
P2860
P304
P356
10.1002/BJS.7574
P407
P577
2011-06-06T00:00:00Z